BERLIN (Reuters) – U.S. pharma giant Eli Lilly plans an investment in the single-digit billion dollar range in a new plant in western Germany, people familiar with the matter told Reuters after the company called a press conference for Friday.
The project will be fully funded by the medicines giant, which has experienced surging demand for diabetes drug Mounjaro, now also being used off-label for weight loss. No details were available on what the plant would produce.
“It’s about an investment in the single-digit billion range,” said an insider of the planned new plant, which will be in the state of Rhineland-Palatinate on the French border, adding that it would need large numbers of skilled workers.
(Reporting by Rene Wagner and Klaus Lauer, writing by Thomas Escritt; Editing by Chizu Nomiyama)
